Investigator-initiated, prospective, non-randomised trial of vernakalant for the treatment of new-onset atrial fibrillation in patients undergoing cardiac interventions.
Phase of Trial: Phase II
Latest Information Update: 17 Feb 2014
Price : $35 *
At a glance
- Drugs Vernakalant (Primary)
- Indications Atrial fibrillation
- Focus Therapeutic Use
- 17 Feb 2014 New trial record
- 13 Feb 2014 Results have been presented at the 43rd Annual Meeting of the Germany Society for Thoracic and Cardiovascular Surgery according to a Cardiome Pharma media release. Results were also reported in the media release.